Keeping Cancer In The Crosshairs

Keeping Cancer In The Crosshairs

Keeping Cancer In The Crosshairs With Targeted Therapies One of the biggest stories in last week’s biotech news headlines was Pfizer’s (New York, NY) acquisition of Array Biopharma (Boulder, CO) for the tidy sum of $11 billion. Array specializes in targeted cancer...
On A Tumor’s Turf

On A Tumor’s Turf

On A Tumor’s Turf  Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of...
PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult...
Breaking Bad With SCLC & NSCLC

Breaking Bad With SCLC & NSCLC

Breaking Down Lung Cancer   The hit TV series Breaking Bad features anti-hero Walter White, who starts out as a sympathetic character: a mild-mannered high school chemistry teacher with a nagging cough that turns out to be lung cancer. Money problems precipitated...
The Multiple Myeloma Landscape

The Multiple Myeloma Landscape

BLOOD CANCER: MULTIPLE MYELOMA Plasma cells are the antibody-producing cells of our immune system which happen to play a critical role in our defense against infections. In multiple myeloma, plasma cells begin to grow and divide in an uncontrolled manner, forming a...
Killing Cancer At Its Stem Cell Origin

Killing Cancer At Its Stem Cell Origin

Killing Cancer When it comes to killing cancer, eradicating every single cell is the goal. But did you know there are different kinds of cancer cells? One specific type, called cancer stem cells (CSC), is catching the eye of drug developers. Discovered more than a...